Published in Eur J Cancer on March 13, 2013
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One (2014) 1.46
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol (2016) 1.40
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One (2013) 1.38
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget (2014) 1.29
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One (2015) 1.26
Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res (2014) 1.23
Unvalidated antibodies and misleading results. Breast Cancer Res Treat (2014) 1.17
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) (2015) 1.14
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia (2013) 1.08
Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol (2015) 1.05
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol (2015) 1.02
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol (2015) 1.00
Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer (2015) 1.00
PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther (2016) 0.98
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res (2015) 0.98
PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer (2014) 0.97
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology (2014) 0.93
PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology (2015) 0.93
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother (2014) 0.92
HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia (2014) 0.90
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget (2016) 0.90
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.89
Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol (2015) 0.88
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther (2015) 0.88
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer (2016) 0.88
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget (2016) 0.87
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget (2015) 0.86
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer (2016) 0.85
Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese. J Cancer Res Clin Oncol (2015) 0.83
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (2016) 0.83
Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. Int J Clin Exp Pathol (2015) 0.83
Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. Onco Targets Ther (2015) 0.82
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget (2016) 0.82
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer (2016) 0.81
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med (2016) 0.81
Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol (2016) 0.80
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep (2016) 0.80
Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med (2015) 0.80
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget (2016) 0.80
Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS One (2016) 0.79
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch (2016) 0.78
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78
Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol (2016) 0.78
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. J Pathol Transl Med (2017) 0.77
SHP-1: the next checkpoint target for cancer immunotherapy? Biochem Soc Trans (2016) 0.77
Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer (2015) 0.77
Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol (2016) 0.77
Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol (2016) 0.76
Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget (2016) 0.76
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. Oncoimmunology (2016) 0.75
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. J Breast Cancer (2016) 0.75
Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci (2017) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther (2016) 0.75
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients. J Pathol Transl Med (2016) 0.75
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine Growth Factor Rev (2016) 0.75
Programmed death-ligand 1 expression in rectal cancer. Eur Surg (2016) 0.75
The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology (2016) 0.75
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Ann Transl Med (2016) 0.75
PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology (2017) 0.75
Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med (2015) 0.75
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int (2016) 0.75
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer (2016) 0.75
PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology (2016) 0.75
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One (2017) 0.75
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther (2017) 0.75
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol (2017) 0.75
PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. J Cancer (2017) 0.75
Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget (2017) 0.75
Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered (2016) 0.75
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. Onco Targets Ther (2017) 0.75
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. Oncoimmunology (2017) 0.75
PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget (2017) 0.75
Bioreactor-engineered cancer tissue-like structures mimic phenotypes, gene expression profiles and drug resistance patterns observed "in vivo". Biomaterials (2015) 0.84
Expression Patterns of TNFα, MAdCAM1 and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. J Crohns Colitis (2017) 0.75